Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Go back to Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 2.75 -0.37 (11.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.12 | 52 Week High | $9.58 | |||
| Open | $2.66 | 52 Week Low | $2.34 | |||
| Day High | $2.85 | P/E | N/A | |||
| Day Low | $2.53 | EPS | $-0.34 | |||
| Volume | 11,219,408 | |||||
